Amgen (AMGN) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $434.03, +1.86% vs the prior close of $426.11.
- Volume 4.63M shares, 1.7x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
AMGN rises 1.9% to $434.03, a 1-month high. Closed at $434.03, +1.86% vs the prior close of $426.11. Day range $433.42–$441.76, opened at $435.83.
AMGN daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — AMGN rises 1.9% to $434.03, a 1-month high
- Closed at $434.03, +1.86% vs the prior close of $426.11. Day range $433.42–$441.76, opened at $435.83.
- Volume was 4.63M shares, 1.7x its 50-day average of 2.78M.
- Price is +4.7% vs its 50-day average ($414.46) and +17.8% vs its 200-day average ($368.38).
- 52-week range $288.00–$447.03; today's close sits at 92% of that range, 2.9% below the 52-week high.
Oct 14, 2026 — AMGN jumps 3.2% to $426.11, a 1-month high
- Closed at $426.11, +3.21% vs the prior close of $412.84. Day range $415.20–$428.05, opened at $417.83.
- Volume was 3.08M shares, 1.1x its 50-day average of 2.80M.
- Price is +2.9% vs its 50-day average ($413.94) and +15.8% vs its 200-day average ($367.86).
- 52-week range $288.00–$447.03; today's close sits at 87% of that range, 4.7% below the 52-week high.
Oct 13, 2026 — AMGN dips 1.1% to $412.84
- Closed at $412.84, -1.13% vs the prior close of $417.57. Day range $411.04–$420.35, opened at $420.34.
- Volume was 2.32M shares, 0.8x its 50-day average of 2.82M.
- Price is -0.1% vs its 50-day average ($413.22) and +12.4% vs its 200-day average ($367.39).
- 52-week range $288.00–$447.03; today's close sits at 79% of that range, 7.6% below the 52-week high.
Oct 12, 2026 — AMGN rises 0.7% to $417.57
- Closed at $417.57, +0.65% vs the prior close of $414.87. Day range $413.44–$417.76, opened at $416.12.
- Volume was 1.72M shares, 0.6x its 50-day average of 2.82M.
- Price is +1.2% vs its 50-day average ($412.54) and +13.8% vs its 200-day average ($367.00).
- 52-week range $288.00–$447.03; today's close sits at 81% of that range, 6.6% below the 52-week high.
Oct 9, 2026 — AMGN rises 1.8% to $414.87
- Closed at $414.87, +1.82% vs the prior close of $407.44. Day range $404.05–$417.78, opened at $405.00.
- Volume was 2.55M shares, 0.9x its 50-day average of 2.83M.
- Price is +0.7% vs its 50-day average ($411.89) and +13.2% vs its 200-day average ($366.57).
- 52-week range $288.00–$447.03; today's close sits at 80% of that range, 7.2% below the 52-week high.
Oct 8, 2026 — AMGN dips 1.4% to $407.44
- Closed at $407.44, -1.37% vs the prior close of $413.08. Day range $400.06–$411.84, opened at $409.97.
- Volume was 2.38M shares, 0.8x its 50-day average of 2.84M.
- Price is -0.9% vs its 50-day average ($411.34) and +11.3% vs its 200-day average ($366.15).
- 52-week range $288.00–$447.03; today's close sits at 75% of that range, 8.9% below the 52-week high.
Oct 7, 2026 — AMGN rises 2.6% to $413.08
- Closed at $413.08, +2.60% vs the prior close of $402.60. Day range $401.85–$415.79, opened at $403.06.
- Volume was 2.24M shares, 0.8x its 50-day average of 2.87M.
- Price is +0.5% vs its 50-day average ($410.95) and +12.9% vs its 200-day average ($365.75).
- 52-week range $288.00–$447.03; today's close sits at 79% of that range, 7.6% below the 52-week high.
Oct 6, 2026 — AMGN ends flat (-0.1%) to $402.60, 5 down days in a row
- Closed at $402.60, -0.09% vs the prior close of $402.98. Day range $396.01–$405.00, opened at $403.30.
- Volume was 2.04M shares, 0.7x its 50-day average of 2.89M.
- Price is -1.9% vs its 50-day average ($410.55) and +10.2% vs its 200-day average ($365.31).
- 52-week range $288.00–$447.03; today's close sits at 72% of that range, 9.9% below the 52-week high.
- That makes 5 straight losses.
Oct 5, 2026 — AMGN ends flat (-0.0%) to $402.98, 4 down days in a row
- Closed at $402.98, -0.01% vs the prior close of $403.04. Day range $397.03–$403.69, opened at $399.03.
- Volume was 3.10M shares, 1.1x its 50-day average of 2.87M.
- Price is -1.7% vs its 50-day average ($410.02) and +10.4% vs its 200-day average ($364.92).
- 52-week range $288.00–$447.03; today's close sits at 72% of that range, 9.9% below the 52-week high.
- That makes 4 straight losses.
Oct 2, 2026 — AMGN dips 1.0% to $403.04, 3 down days in a row
- Closed at $403.04, -1.04% vs the prior close of $407.27. Day range $401.96–$410.16, opened at $410.16.
- Volume was 3.51M shares, 1.2x its 50-day average of 2.86M.
- Price is -1.6% vs its 50-day average ($409.48) and +10.6% vs its 200-day average ($364.54).
- 52-week range $288.00–$447.03; today's close sits at 72% of that range, 9.8% below the 52-week high.
- That makes 3 straight losses.
AMGN latest news & SEC filings
Every SEC filing by or about AMGN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 4, 2026 · 3 — Initial insider ownership statement (Form 3)
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 13, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Khosla Rachna sold 1,252 shares at $416.43 (≈$521.37K) on Aug 13, 2026
- Khosla Rachna sold 2,000 shares at $412.57 (≈$825.14K) on Aug 11, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 13, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 12, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 11, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 10, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 5, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $10.05B (prior year $9.18B) (+9.5% vs Jun 30, 2025)
- Net income: $2.38B (prior year $1.43B) (+65.9% vs Jun 30, 2025)
- Diluted EPS: $4.37 (prior year $2.65) (+64.9% vs Jun 30, 2025)
Aug 4, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 31, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.05 — Material cybersecurity incident.
Things to know before you trade AMGN
- Last results release: Aug 4, 2026 (8-K Item 2.02). Previous ones: Apr 30, 2026, Feb 3, 2026, Nov 4, 2025. Based on that rhythm, the next report is likely around Nov 3, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.54% (largest 4.3%).
- Liquidity: about 3.13M shares (≈$1.36B) trade per day on average.
- 52-week position: $434.03 vs a range of $288.00–$447.03 (92% of the range).
- Dividends: last ex-dividend date Aug 21, 2026 ($2.52/share); 4 payments in the past 12 months.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 14 sales; latest: Rachna Khosla sold 1,252 shares on Aug 13, 2026.
- Latest filings: 10-Q Aug 5, 2026; 8-K Aug 4, 2026; 8-K Jul 31, 2026.
- Share count: 540.63M shares outstanding (Jul 30, 2026), +0.4% vs a year earlier.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
AMGN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 435.83 | 441.76 | 433.42 | 434.03 | 4.63M |
| Oct 14, 2026 | 417.83 | 428.05 | 415.20 | 426.11 | 3.08M |
| Oct 13, 2026 | 420.34 | 420.35 | 411.04 | 412.84 | 2.32M |
| Oct 12, 2026 | 416.12 | 417.76 | 413.44 | 417.57 | 1.72M |
| Oct 9, 2026 | 405.00 | 417.78 | 404.05 | 414.87 | 2.55M |
| Oct 8, 2026 | 409.97 | 411.84 | 400.06 | 407.44 | 2.38M |
| Oct 7, 2026 | 403.06 | 415.79 | 401.85 | 413.08 | 2.24M |
| Oct 6, 2026 | 403.30 | 405.00 | 396.01 | 402.60 | 2.04M |
| Oct 5, 2026 | 399.03 | 403.69 | 397.03 | 402.98 | 3.10M |
| Oct 2, 2026 | 410.16 | 410.16 | 401.96 | 403.04 | 3.51M |
| Oct 1, 2026 | 421.72 | 422.80 | 407.13 | 407.27 | 2.50M |
| Sep 30, 2026 | 424.01 | 426.59 | 420.63 | 421.51 | 3.13M |
| Sep 29, 2026 | 414.37 | 424.57 | 414.11 | 423.64 | 3.74M |
| Sep 28, 2026 | 411.52 | 419.02 | 410.96 | 418.13 | 2.92M |
| Sep 25, 2026 | 408.25 | 415.20 | 404.19 | 414.61 | 2.21M |
| Sep 24, 2026 | 406.09 | 409.99 | 403.88 | 406.04 | 2.52M |
| Sep 23, 2026 | 410.09 | 415.76 | 404.34 | 406.09 | 2.82M |
| Sep 22, 2026 | 405.25 | 413.00 | 398.52 | 410.24 | 3.72M |
| Sep 21, 2026 | 385.71 | 394.50 | 381.90 | 393.16 | 2.89M |
| Sep 18, 2026 | 378.51 | 386.50 | 378.51 | 385.65 | 8.52M |
About Amgen
Amgen (AMGN) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in THOUSAND OAKS, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 318154.
AMGN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Wanda M Austin | Director | May 21, 2026 |
| Robert A Bradway | Chairman, CEO and President | May 11, 2026 |
| Michael V Drake | Director | Aug 10, 2026 |
| Brian Druker | Director | May 21, 2026 |
| Robert Eckert | Director | May 21, 2026 |
| Greg C. Garland | Director | May 21, 2026 |
| Charles M Holley | Director | Aug 10, 2026 |
| Omar Ishrak | Director | Aug 10, 2026 |
| Tyler Jacks | Director | May 21, 2026 |
| Mary E. Klotman | Director | May 21, 2026 |
| Ellen Jamison Kullman | Director | May 21, 2026 |
| Amy E Miles | Director | May 21, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| James E. Bradner | EVP, Research and Development | May 11, 2026 |
| Robert A Bradway | Chairman, CEO and President | May 11, 2026 |
| Matthew C. Busch | VP, Finance & CAO | Aug 12, 2026 |
| Thomas J.W. Dittrich | EVP & CFO | Sep 4, 2026 |
| Murdo Gordon | EVP, Global Commercial Ops | May 11, 2026 |
| Jonathan P Graham | EVP & Gen. Counsel & Sec. | May 11, 2026 |
| Peter H. Griffith | EVP & CFO | May 11, 2026 |
| Nancy A. Grygiel | SVP & CCO | Aug 7, 2026 |
| Rachna Khosla | SVP, Business Development | Aug 13, 2026 |
| Derek Miller | SVP, Human Resources | Aug 7, 2026 |
| David M Reese | EVP & Chief Technology Officer | May 11, 2026 |
| Esteban Santos | EVP, Operations | May 11, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 13, 2026 | Rachna Khosla | Sale | 1,252 | $416.43 |
| Aug 11, 2026 | Rachna Khosla | Sale | 2,000 | $412.57 |
| Aug 6, 2026 | Nancy A. Grygiel | Sale | 1,000 | $402.16 |
| Aug 6, 2026 | Nancy A. Grygiel | Sale | 1,970 | $402.16 |
| Aug 6, 2026 | Derek Miller | Sale | 2,069 | $402.54 |
| Aug 6, 2026 | Derek Miller | Sale | 1,821 | $402.54 |
| May 4, 2026 | Nancy A. Grygiel | Sale | 1,237 | $323.73 |
| Feb 26, 2026 | Esteban Santos | Sale | 24,291 | $379.12 |
| Feb 26, 2026 | Esteban Santos | Sale | 30,501 | $379.12 |
| Feb 19, 2026 | Matthew C. Busch | Sale | 1,000 | $375.79 |
| Nov 20, 2025 | Nancy A. Grygiel | Sale | 1,639 | $337.26 |
| Nov 20, 2025 | Nancy A. Grygiel | Sale | 1,500 | $337.26 |
| Nov 12, 2025 | Murdo Gordon | Sale | 6,879 | $336.83 |
| Nov 12, 2025 | Rachna Khosla | Sale | 890 | $336.24 |
AMGN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $36.75B | $7.71B | 14.23 | $9.96B |
| Dec 31, 2024 | $33.42B | $4.09B | 7.56 | $11.49B |
| Dec 31, 2023 | $28.19B | $6.72B | 12.49 | $8.47B |
| Dec 31, 2022 | $26.32B | $6.55B | 12.11 | $9.72B |
| Dec 31, 2021 | $25.98B | $5.89B | 10.28 | $9.26B |
Latest balance sheet: total assets $95.64B, total liabilities $—, cash $13.99B (as of Jun 30, 2026).
AMGN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 4, 2026 | 8-K Item 2.02 (results) | $390.02 |
| Apr 30, 2026 | 8-K Item 2.02 (results) | $346.25 |
| Feb 3, 2026 | 8-K Item 2.02 (results) | $338.59 |
| Nov 4, 2025 | 8-K Item 2.02 (results) | $296.70 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $300.08 |
| May 1, 2025 | 8-K Item 2.02 (results) | $283.78 |
| Feb 4, 2025 | 8-K Item 2.02 (results) | $289.02 |
| Oct 30, 2024 | 8-K Item 2.02 (results) | $315.54 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 2, 2024 | 8-K Item 2.02 (results) | — |
| Feb 6, 2024 | 8-K Item 2.02 (results) | — |
| Oct 31, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)Repligen (RGEN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on AMGN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.